Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1-Infected Patients with Central Nervous System Impairment.
central nervous system diffusion
central nervous system impairment
cerebrospinal fluid
dolutegravir
pharmacokinetics
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
16
11
2018
accepted:
17
05
2019
entrez:
15
6
2019
pubmed:
15
6
2019
medline:
15
6
2019
Statut:
epublish
Résumé
This study aimed to determine dolutegravir cerebrospinal fluid (CSF) diffusion in 13 patients with HIV-related cerebral impairment enrolled in a real-life observational study. Dolutegravir median (range) CSF concentration [9.6 (3.6-22.8) ng/mL] reached CSF therapeutic concentrations whatever the blood-brain barrier status and diffused in correlation with the albumin quotient (
Identifiants
pubmed: 31198814
doi: 10.1093/ofid/ofz174
pii: ofz174
pmc: PMC6546201
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz174Références
Nat Rev Immunol. 2005 Jan;5(1):69-81
pubmed: 15630430
AIDS. 2010 Jun 1;24(9):1243-50
pubmed: 19996937
Antimicrob Agents Chemother. 2011 Feb;55(2):813-21
pubmed: 21115794
AIDS. 2011 Sep 10;25(14):1737-45
pubmed: 21716073
Clin Infect Dis. 2014 Oct;59(7):1032-7
pubmed: 24944232
Lancet HIV. 2015 Apr;2(4):e127-36
pubmed: 26424673
Nature. 2016 Feb 4;530(7588):51-56
pubmed: 26814962
Neurol Neuroimmunol Neuroinflamm. 2016 Nov 09;3(6):e300
pubmed: 27868081
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28348149
Curr Opin HIV AIDS. 2018 Mar;13(2):102-111
pubmed: 29278532
Scand J Clin Lab Invest. 1977 Sep;37(5):391-6
pubmed: 337460